Beijing Succeeder Technology Inc
SSE:688338
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (35.4), the stock would be worth ¥27.01 (10% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 39.4 | ¥30.08 |
0%
|
| 3-Year Average | 35.4 | ¥27.01 |
-10%
|
| 5-Year Average | 38 | ¥29.01 |
-4%
|
| Industry Average | 31.4 | ¥23.91 |
-20%
|
| Country Average | 26.4 | ¥20.13 |
-33%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
B
|
Beijing Succeeder Technology Inc
SSE:688338
|
3.2B CNY | 39.4 | 32.4 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.4T JPY | 48.7 | 37.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
28.4B CHF | 26.3 | 36.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
88.8B DKK | 18 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.8B USD | 26 | 31.1 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.8B USD | -25.4 | -16 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.1B GBP | 12.6 | 31.1 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
37.9B CNY | 33.7 | 23 | |
| CN |
|
Intco Medical Technology Co Ltd
SZSE:300677
|
37.3B CNY | 10.3 | 21.9 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.1T KRW | -115.1 | -36.5 |
Market Distribution
| Min | 0.2 |
| 30th Percentile | 13.7 |
| Median | 26.4 |
| 70th Percentile | 52.8 |
| Max | 2 279 450.9 |
Other Multiples
Beijing Succeeder Technology Inc
Glance View
Beijing Succeeder Technology, Inc. engages in research, development, production, and sales of detection instruments, reagents, and consumables for thrombosis and hemostasis in the in-vitro diagnosis field. The company is headquartered in Beijing, Beijing and currently employs 266 full-time employees. The company went IPO on 2020-08-06. The firm provides medical institutions with automated detection equipment for blood coagulation, blood rheology, hematocrit, platelet aggregation, and supporting reagents and consumables. Its products include testing instruments, reagents and consumables, such as automatic coagulation testers, coagulation quality control kits, Newtonian fluid quality controls, reaction cups and SAW blood rheology special cleaning. The firm operates its businesses within the domestic market and to overseas markets.
